Paul Hastings's early work on the novel drug Alpha Interferon made him a rare talent sought after by new biotech startups. Specializing in a new technology before it's mainstream offers a significant career advantage and propels you into leadership roles.
Paul Hastings's lifelong battle with Crohn's disease has fueled his 40-year passion for biotech. This personal connection to patient needs provides a deeper, more resilient source of energy than typical career ambition, especially in high-failure industries like drug development.
NKarta differentiates its CAR NK therapy by highlighting its transient nature. Unlike CAR T cells that expand and can cause severe side effects, NK cells act quickly and exit the body, positioning it as a safer, 'off-the-shelf' option for diseases needing rapid B-cell depletion.
The system's over-reliance on a few large academic centers in major cities creates a massive bottleneck. Paul Hastings argues for empowering community-based research centers where most patients live to dramatically increase enrollment speed, diversity, and US competitiveness.
Paul Hastings argues that while FDA leaders talk about speeding up trials, they only consult elite academics. To truly understand the landscape, they must engage with community-based physicians who treat the vast majority of patients and understand real-world clinical challenges.
Paul Hastings describes how he now learns from his former mentees who have become CEOs. Their different career paths and modern approaches offer new perspectives, transforming the traditional one-way mentorship model into a reciprocal, full-circle learning relationship.
A CEO's willingness to speak forcefully on topics like Diversity, Equity, and Inclusion can be a powerful motivator. An employee told Paul Hastings's entire company that his unapologetic stance on DEI was a primary reason she wanted to work there, proving that values-based leadership builds strong loyalty.
Paul Hastings recounts dinners with his mentor, Genzyme CEO Henry Termeer, who would ask about specific, non-executive employees by name across global offices. This granular, personal interest in his 6,000-person team demonstrated a profound level of care that inspired deep loyalty.